Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization
出版年份 2016 全文链接
标题
Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization
作者
关键词
-
出版物
MODERN PATHOLOGY
Volume 29, Issue 9, Pages 1038-1049
出版商
Springer Nature
发表日期
2016-06-17
DOI
10.1038/modpathol.2016.111
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma
- (2015) Beom Kyung Kim et al. JOURNAL OF HEPATOLOGY
- Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation
- (2015) Oriana Miltiadous et al. JOURNAL OF HEPATOLOGY
- Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2
- (2015) H Fan et al. ONCOGENE
- Visualization of stem cell features in human hepatocellular carcinoma revealsin vivosignificance of tumor-host interaction and clinical course
- (2013) Shunsuke Muramatsu et al. HEPATOLOGY
- How to decide about liver transplantation in patients with hepatocellular carcinoma: Size and number of lesions or response to TACE?
- (2013) Gerd Otto et al. JOURNAL OF HEPATOLOGY
- Molecular Mechanisms of HBV-Associated Hepatocarcinogenesis
- (2013) Francesca Guerrieri et al. SEMINARS IN LIVER DISEASE
- A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition
- (2012) Jae Yeon Seok et al. HEPATOLOGY
- Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity
- (2012) Margaret J. Currie et al. HUMAN PATHOLOGY
- 1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY
- (2012) J.M. Llovet et al. JOURNAL OF HEPATOLOGY
- Marginal survival benefit in the treatment of early hepatocellular carcinoma
- (2012) Yutaka Midorikawa et al. JOURNAL OF HEPATOLOGY
- Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche
- (2012) F E Lock et al. ONCOGENE
- Does the Hepatitis B Antigen HBx Promote the Appearance of Liver Cancer Stem Cells?
- (2011) A. Arzumanyan et al. CANCER RESEARCH
- Targeting HIF1α Eliminates Cancer Stem Cells in Hematological Malignancies
- (2011) Yin Wang et al. Cell Stem Cell
- Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis
- (2011) Haeryoung Kim et al. HEPATOLOGY
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Beyond the Milan Criteria
- (2011) Luciano De Carlis et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization
- (2011) Roopinder Gillmore et al. JOURNAL OF HEPATOLOGY
- Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report
- (2011) Pierre-Alain Clavien et al. LANCET ONCOLOGY
- The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype
- (2010) John M. Heddleston et al. CELL CYCLE
- Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma
- (2009) Terence C. Chua et al. LIVER INTERNATIONAL
- Early Hepatocellular Carcinoma: Pathology, Imaging, and Therapy
- (2008) Tadatoshi Takayama et al. ANNALS OF SURGICAL ONCOLOGY
- Recurrence of Hepatocellular Carcinoma Following Liver Transplantation
- (2008) Michael A. Zimmerman ARCHIVES OF SURGERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started